循证医学：前景与陷阱 - Suppr

Suppr

超能文献

Evidence-based medicine: promise and pitfalls.

作者信息

Goodin Douglas S, Reder Anthony T

机构信息

University of California, San Francisco, Neurology, San Francisco, CA 94143-0114, USA.

出版信息

Mult Scler. 2012 Jul;18(7):947-8. doi: 10.1177/1352458512451660.

DOI:10.1177/1352458512451660

PMID:22740607

Abstract

摘要

相似文献

Evidence-based medicine: promise and pitfalls.循证医学：前景与陷阱

Mult Scler. 2012 Jul;18(7):947-8. doi: 10.1177/1352458512451660.

[Drug therapy of multiple sclerosis].

Duodecim. 1999;115(4):403-7.

[Better life expectations of SM patients: 21 years follow up of patients treated with interferon beta-1b].[脊髓性肌萎缩症患者更好的生活预期：接受β-1b干扰素治疗患者的21年随访]

Ideggyogy Sz. 2013 Mar 30;66(3-4):143-4.

Pearls and pitfalls of interferon beta treatment for multiple sclerosis.干扰素β治疗多发性硬化症的要点与陷阱

Neurologia. 1999 Nov;14(9):467-8.

Seeing injectable ms therapies differently: they are more similar than different.以不同视角看待注射用多发性硬化症疗法：它们的相似之处多于不同之处。

Neurology. 2010 Feb 23;74(8):702. doi: 10.1212/WNL.0b013e3181c77773.

[The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments].[BCTRIMS关于多发性硬化治疗的扩展共识：II. 糖皮质激素和免疫调节治疗的应用证据]

Arq Neuropsiquiatr. 2002 Sep;60(3-B):875-80.

10 years of interferon beta-1b (Beta feron therapy.

J Neurol. 2005 Sep;252 Suppl 3:iii1-iii2. doi: 10.1007/s00415-005-2009-z.

[Betaferon and therapy of multiple sclerosis--present and future].[β-干扰素与多发性硬化症的治疗——现状与未来]

Med Klin (Munich). 2001 Sep 15;96 Suppl 1:1.

The AAN response to evidence-based medicine: promise and pitfalls.美国神经病学学会对循证医学的回应：前景与困境

Mult Scler. 2012 Jul;18(7):949-50. doi: 10.1177/1352458512448449.

["The largest snapshot of multiple sclerosis". Interferons compared].["多发性硬化症的最大规模快照"。干扰素对比]

MMW Fortschr Med. 2003 Jun 12;145(24):55.

引用本文的文献

Development and validation of a convenient formula evaluating the value and applicability of medical literature in clinical practice.一种评估医学文献在临床实践中的价值和适用性的便捷公式的开发与验证。

Pak J Med Sci. 2014 Nov-Dec;30(6):1377-82. doi: 10.12669/pjms.306.5450.

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.肿瘤学中的患者相关终点：德国早期获益评估背景下的当前问题。

Health Econ Rev. 2014 Jan 24;4(1):2. doi: 10.1186/2191-1991-4-2.

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.多发性硬化症的死因：关键性 IFNβ-1b 研究开始 21 年后的随机队列长期随访。

BMJ Open. 2012 Nov 30;2(6). doi: 10.1136/bmjopen-2012-001972. Print 2012.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验